TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01313793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A-B
Description: Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B-A
Description: Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
Study: NCT04438252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CariScan Pro
Description: Device for early caries detection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Digital Radiograpgy
Description: Device for digital x-ray imaging
Study: NCT00778986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart failure remote patient monitoring system
Description: remote monitoring of weight, blood pressure, ECG, and symptoms
Study: NCT01900756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THRIVES
Description: Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
Study: NCT03550638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil system(Ton-bridgeMT)
Description: 1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axium Detachable Coil(Medtronic)
Description: 2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
Study: NCT02030132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forgiveness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forgiveness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
Study: NCT00164736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maternal zidovudine/lamivudine/lopinavir-ritonavir
Description: Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maternal zidovudine/lamivudine/lopinavir-ritonavir
Description: Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infant nevirapine
Description: Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infant nevirapine
Description: Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maternal protein and calorie supplement
Description: High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maternal protein and calorie supplement
Description: High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maternal protein and calorie supplement
Description: High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
Study: NCT03624218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
Study: NCT04172909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEGO Bricks MRI
Description: LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mock MRI tube
Description: Mock MRI tube will be used by the child life specialist to prepare the child for MRI
Study: NCT05454930

Intervention type: OTHER
Group type: OTHER
Intervention: Filtered Air
Description: The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
Study: NCT03203954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Learning
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Study: NCT02030132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
Study: NCT03203954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Learning: Instructed statistics
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Learning: Changing statistics
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Study: NCT04440319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
Study: NCT03567941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study: NCT02275598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD
Description: Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
Study: NCT03170557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chinese acupuncture
Description: Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aspecific needle skin stimulation
Description: Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
Study: NCT00493974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zileuton
Description: Zyflo tablets, 600 mg, 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 x daily
Study: NCT02766790

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65MD
Description: TA-65, a purified small molecule extracted from Astragalus root

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65MD
Description: TA-65, a purified small molecule extracted from Astragalus root

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65MD
Description: TA-65, a purified small molecule extracted from Astragalus root

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65MD
Description: TA-65, a purified small molecule extracted from Astragalus root

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, an inactive formulation
Study: NCT03345433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive group drumming sessions
Description: interactive group drumming sessions
Study: NCT01244191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tivantinib Placebo tablets given twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg oral tablets, given once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg oral tablets, given once a day
Study: NCT02921763

Intervention type: DRUG
Intervention: Dydrogesterone
Study: NCT04609995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: No financial incentive

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: No financial incentive
Study: NCT00845546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
Study: NCT00642018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308 sodium
Description: LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
Study: NCT03567941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study: NCT00642018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
Study: NCT04312438

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral food challenge with cow's milk proteins
Description: in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
Study: NCT02833376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol antisepsis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine antisepsis
Study: NCT04244201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaporous Hyperoxia Therapy
Description: 1 hour of treatment, 4 times per week
Study: NCT02050425

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-CPAP device
Description: short-term CPAP withdrawal by the use of Placebo-CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Patients continue therapeutic CPAP therapy
Study: NCT02681224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TR987 Gel with Silon Bandage
Description: Novel healing gel with occlusive dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TR987 without Silon Bandage
Description: Novel healing gel without occlusive dressing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel with Silon Bandage
Description: Placebo gel with occlusive dressing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel without Silon Bandage
Description: Placebo Gel without occlusive dressing
Study: NCT02540317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
Study: NCT01415219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active rehabilitation
Description: A program of 12 individual exercise sessions (3 per week during 4 weeks)
Study: NCT04327856

Intervention type: PROCEDURE
Intervention: Cataract Surgery
Description: The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
Study: NCT01530763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)
Study: NCT03567941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reference
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Tablet orally administered under fasted conditions
Study: NCT01307267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Intravenous, Dose escalation, once per month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous, 375 mg/m2, once per week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: IV, Dose escalation, once per month
Study: NCT01183936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-cm margin
Description: Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
Study: NCT01530763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clavulanate
Description: Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin clavulanate
Description: Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)
Study: NCT01939925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New plain language summary format
Description: New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current plain language summary format
Description: Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
Study: NCT03764436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAPS-NCHD Program
Description: The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAPS-NCHD Program
Description: The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAPS-NCHD Program
Description: The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
Study: NCT01183936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-cm margin
Description: Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
Study: NCT04592575

Intervention type: OTHER
Intervention: Vestibular Evaluation
Description: Each patient will have a full vestibular evaluation by a physical therapist

Intervention type: OTHER
Intervention: Vestibular Evaluation
Description: Each patient will have a full vestibular evaluation by a physical therapist
Study: NCT04700189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ab interno canaloplasty
Description: A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
Study: NCT04066725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants will be given ASA 81 mg orally once daily for a total of 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Participants will be given ASA 325 mg orally once daily for a total of 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants will be given placebo orally once daily for a total of 60 days
Study: NCT03015311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP control
Description: For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP control
Description: For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
Study: NCT01402531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Submucosal Bevacizumab
Description: 200 mg Bevacizumab, injected submucosally- 100 mg per nostril
Study: NCT03020979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will take 500mg apatinib daily orally.
Study: NCT03795194

Intervention type: DRUG
Group type: OTHER
Intervention: ampicillin/clavulanate
Description: FDA-approved antibiotic

Intervention type: DRUG
Group type: OTHER
Intervention: ampicillin/clavulanate
Description: FDA-approved antibiotic
Study: NCT03567252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Group
Description: Participants will walk 1 kilometer to a Farmer's Market.